| Literature DB >> 35937405 |
Lei Yan1, Yuan Li1, Chunye Wu1, Yuquan Shi1, Chunyu Kong1.
Abstract
Background: Fungal infection in the lungs can cause fungal infectious diseases. This disease develops rapidly and involves a wide range. Pathogenic fungi are also more serious types of pathogenic bacteria. If it invades deep organs and tissues, it will endanger life, so it needs timely diagnosis. Aim: To investigate the diagnostic value of serum soluble myeloid cell triggering receptor-1 (sTREM-1), procalcitonin (PCT), and 1,3-β-D glucan detection in immune related lung disease complicated with fungal infection.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35937405 PMCID: PMC9348935 DOI: 10.1155/2022/6095441
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.246
General data comparison.
| Infection group ( | Control group ( |
|
| |
|---|---|---|---|---|
| Age (years) | 64.8 ± 7.1 | 66.1 ± 6.8 | -0.935 | 0.352 |
| BMI (kg/m2) | 23.67 ± 1.83 | 24.03 ± 1.72 | -1.014 | 0.313 |
| Gender (%) | 1.714 | 0.190 | ||
| Male | 32 (64) | 38 (76) | ||
| Female | 18 (36) | 12 (24) | ||
| Smoking (%) | 1.961 | 0.161 | ||
| Yes | 21 (42) | 28 (56) | ||
| No | 29 (58) | 22 (44) | ||
| Drinking (%) | 1.131 | 0.288 | ||
| Yes | 19 (38) | 14 (28) | ||
| No | 31 (62) | 36 (72) | ||
| Concomitant disease (%) | ||||
| Hypertension | 21 (42) | 28 (56) | 1.961 | 0.161 |
| Diabetes | 16 (32) | 11 (22) | 1.268 | 0.260 |
| Coronary heart disease | 6 (12) | 3 (6) | 1.099 | 0.295 |
| Hyperlipidemia | 19 (38) | 23 (46) | 0.657 | 0.418 |
Comparison of fungal infection types and drug resistance types in 50 patients in infection group.
| Fungus type |
| Itraconazole | Voriconazole | Fluconazole | Amphotericin B | ||||
|---|---|---|---|---|---|---|---|---|---|
| Number of resistant strains | Resistance rate (%) | Number of resistant strains | Resistance rate (%) | Resistance rate (%) | Number of resistant strains | Number of resistant strains | Resistance rate (%) | ||
| Aspergillus | 16 | 4 | 25.00% | 6 | 37.50% | 12 | 75.00% | 4 | 25.00% |
| Candida albicans | 9 | 1 | 11.11% | 2 | 22.22% | 4 | 44.44% | 2 | 22.22% |
| Candida glabrata | 6 | 1 | 16.67% | 1 | 16.67% | 2 | 33.33% | 1 | 16.67% |
| Candida krusei | 8 | 1 | 12.50% | 2 | 25.00% | 3 | 37.50% | 1 | 12.50% |
| Candida tropicalis | 6 | 0 | 0.00% | 0 | 0.00% | 3 | 50.00% | 3 | 50.00% |
| Candida parapsilosis | 5 | 0 | 0.00% | 1 | 20.00% | 2 | 40.00% | 1 | 20.00% |
Comparison of the levels of sTREM-1, PCT, and 1,3-β-D glucan between the infection group and the control group ().
| Group | n | sTREM-1 (ng/L) | PCT (ng/L) | 1,3- |
|---|---|---|---|---|
| Infection group | 50 | 54.19 ± 9.57 | 577.4 ± 97.4 | 43.57 ± 14.84 |
| Control group | 50 | 33.20 ± 5.58 | 448.1 ± 56.0 | 8.30 ± 3.13 |
|
| 13.398 | 8.138 | 16.444 | |
|
| <0.01 | <0.01 | <0.01 |
Figure 1ROC chart of sTREM-1, PCT, and 1,3-β-D glucan in the diagnosis of immune-related lung diseases complicated by fungal infection.
Comparison of sTREM-1, PCT, and 1,3-β-D glucan levels before and after treatment ().
| Time |
| sTREM-1 (ng/L) | PCT (ng/L) | 1,3- |
|---|---|---|---|---|
| Before therapy | 50 | 54.19 ± 9.57 | 577.4 ± 97.4 | 43.57 ± 8.84 |
| After treatment | 50 | 39.66 ± 7.40 | 483.5 ± 66.1 | 22.50 ± 5.58 |
|
| 8.493 | 5.641 | 14.252 | |
|
| <0.01 | <0.01 | <0.01 |